Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
17 hedge funds and large institutions have $1.52M invested in Iterum Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
711% more capital invested
Capital invested by funds: $187K → $1.52M (+$1.33M)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
1.94% more ownership
Funds ownership: 1.47% → 3.41% (+1.9%)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
+$221K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$83K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.6K |
| 4 |
Renaissance Technologies
New York
|
+$4.32K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$46 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KF
Krilogy Financial
St. Louis,
Missouri
|
-$20K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.7K |
| 3 |
FWM
Focused Wealth Management
Newburgh,
New York
|
-$6.67K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$133 |
ITRM Hedge Fund Activity: Q2 2023 in Review
17 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q2 2023, worth a combined $1.52M — up 711% from $187K a quarter earlier.
Fund positioning in ITRM was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Apollon Wealth Management, opening a new position worth an estimated $221K. The largest seller was Krilogy Financial, exiting entirely with an estimated $20K sold.
- 17 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $1.52M of Iterum Therapeutics stock for Q2 2023, up 711% quarter-over-quarter.
- 3 funds opened new Iterum Therapeutics positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Iterum Therapeutics buyer in Q2 2023 was Apollon Wealth Management, an estimated $221K added.
- The largest Iterum Therapeutics seller in Q2 2023 was Krilogy Financial, an estimated $20K sold.
Based on aggregated 13F filings for Q2 2023.